Tiziana Life Sciences Ltd. Common Shares (TLSA) Stock Price
TLSAStock
$1.11−44.17%52W
Market Cap$141.26M
P/E—
PEG Ratio—
Div yield—
Beta0.23
TLSA Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-29.10%
Price vs S&P 500 (4W)15.85%
VGM Score34.35
TLSA Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(571)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
TLSATiziana Life Sciences Ltd. Common Shares | — | — | D | $1.11 |
| LLYEli Lilly & Co. | D | B | B | $1233.66 |
| JNJJohnson & Johnson | D | C | B | $273.14 |
| ABBVABBVIE INC. | D | C | B | $265.79 |
| MRKMerck & Co., Inc. | D | C | A | $156.45 |
| NVSNovartis AG | C | C | C | $159.98 |
| AZNAstraZeneca PLC | C | B | C | $169.66 |
| NVONovo-Nordisk A/S | B | C | C | $48.66 |
| ABTAbbott Laboratories | C | C | B | $116.13 |
| PFEPfizer Inc. | C | D | C | $28.57 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $552.85 |
About Tiziana Life Sciences Ltd. Common Shares
Tiziana Life Sciences is a clinical-stage biotechnology company developing immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's lead candidate, Foralumab (a fully human anti-CD3 monoclonal antibody), is in development for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's disease, and other CNS indications. Its pipeline also includes programs for ALS.